These pharmaceutical companies earned 2 billion yuan in half a year.

According to incomplete statistics, more than 280 pharmaceutical companies have issued semi-annual reports, with only 8 loss-making companies and a loss of 2.85% (281 pharmaceutical companies' detailed performance). The list is turned to the end of the article. It is much more optimistic than the data of China's pharmaceutical industry issued by China Merchants Research Institute for half a year. This shows that most listed pharmaceutical companies in China have relatively good profitability.

According to the data disclosed by the China Business Research Institute, from January to June 2018, the main business income was 1,257.73 billion yuan, and the total profit was 158.57 billion yuan; the growth rate was 13.5% and 14.4% respectively.

The statistics of the China Merchants Research Institute disclosed more than 7,400 pharmaceutical companies, including 1,214 loss-making enterprises, with a loss of 16.21%, a total loss of 6.27 billion yuan, and a loss increase of 28.7%. It can be seen that in recent years, medical insurance fees, two The influence of the voting system and other policies on the performance of pharmaceutical companies has gradually emerged.

According to the statistics of 281 listed pharmaceutical companies, the total operating income reached 690 billion yuan and the net profit was 66.69 billion yuan. Among them, 273 profitable enterprises, total net profit of 67.838 billion yuan, 8 loss-making enterprises, and loss of 1.269 billion yuan. yuan.

Note: The data comes from the Eastern Fortune Network; the enterprise classification is based on the letter, for reference.

In addition to Kangchen Pharmaceutical's recent listing transaction, it has not disclosed the complete semi-annual report. It can't compare with 280 pharmaceutical companies compared with the same period of last year. In addition to biopharmaceuticals, Shanghai Lai Shi has a high net profit and net profit margin. Due to the huge loss of over 800 million stocks, the whole category has basically no growth, and the other categories have achieved substantial growth, of which the chemical pharmaceutical and healthcare industries have increased by more than 30%.

In terms of net profit, both Chinese patent medicines and chemical pharmaceuticals are above 22 billion yuan, of which Chinese patent medicines record the highest net profit.

From the perspective of profit margin, the net profit margin of comparable 280 pharmaceutical companies was basically the same as that of the same period of last year. Among them, the profit rate of proprietary Chinese medicines reached 14.44% in the first half of this year, which is the first place with Shanghai Lace. The profit rate dropped sharply by more than 7 percentage points and fell back to the second place.

Note: The data comes from Eastern Fortune Network; the enterprise classification is based on Tongdaxin, the profit margin is changed compared with the same period of last year = 2018H1 net profit margin - 2017H1 net profit margin, for reference.

Among the 281 pharmaceutical companies, nearly 60% of pharmaceutical companies had net profit of over 100 million yuan in the first half of 2018, compared with less than half in the same period of 2017; 36 pharmaceutical companies with more than 500 million yuan, an increase of 6 over the same period last year; The drug enterprises of 1 billion yuan have increased by 3 compared with the same period of last year. More than 2 billion yuan last year was only 2, and this year reached 4. Among them, the pharmaceutical companies with net profit of more than 2 billion yuan in the first half of 2018 are as follows:

Note: The data comes from the Eastern Fortune Network; the enterprise classification is based on the letter, for reference.

Among the pharmaceutical companies with a net profit of more than 2 billion yuan, two are Chinese patent medicine companies. It can be seen that although Chinese medicine companies, especially injection companies, have been restricted by the development of auxiliary drugs and monitoring drugs in the past two years, they have better integration. Ability, can achieve economies of scale, have traditional Zhongcheng drug Enterprises have strong ability to make money.

In addition, Kangmei Pharmaceutical and Shanghai medicine The net profit of the same period last year was also more than 2 billion yuan, showing that the two pharmaceutical companies have better profitability.

In the first half of 2018, Baiyunshan achieved an operating income of 14.840 billion yuan, a year-on-year increase of 33.51%; net profit of RMB 2.619 billion, an increase of 126.14% over the same period of last year. There are three main reasons for the large increase:

1 Increase market expansion, and achieve rapid development of many large varieties. Jin Ge, Banlangen granules, Guanghua Xiaochaihu granules, Pan Gaoshou honey refining Chuanbei glutinous cream, Chen Liji Zhuangyao Jianshen Pill and other key varieties were all recorded. Substantial growth.

2 Through the capital mergers and acquisitions to increase the performance, the major asset purchases that acquired the 30% equity of Guangzhou Pharmaceutical Co., Ltd. in cash completed the asset delivery and industrial and commercial change registration on May 31, 2018, achieving a consolidated view, resulting in a substantial increase in profits year-on-year. .

3 Capital investment gains value-added income. The company participates in the non-public offering of shares of Yixintang Company. In 2018, the added value of 255 million yuan was included in the profit, which increased the current profit.

In the first half of 2018, Kangmei Pharmaceutical achieved a total operating income of 16.959 billion yuan, an increase of 27.88% over the same period of the previous year, and a net profit of 2,581,985,900 yuan, an increase of 20.32% over the same period of the previous year.

Kangmei Pharmaceutical focuses on the two major development themes of Chinese medicine industry chain and big health industry, and builds a precision service type 'smart + big health' industrial service system for the whole industry chain of traditional Chinese medicine, and promotes the upgrading of large health industry.

Expand business beyond the main business. Make full use of the market opportunity brought by a series of policies such as drug consistency evaluation, two-vote system, and integrate high-quality resources in various ways such as investment, mergers and acquisitions, etc. medical instruments Sales platform, fast access to GSP qualifications, expansion of pharmaceutical and medical device distribution business; investment management public hospitals to supplement the company's medical resources, to seize the medical terminal market.

Shanghai Pharmaceutical's main business continued to grow rapidly. In the first half of the year, its operating income was 75.789 billion yuan, a year-on-year increase of 15.35%.

Among them, the pharmaceutical industry realized revenue of 9.627 billion yuan, a year-on-year increase of 28.31%, and contributed a profit of 906 million yuan, a year-on-year increase of 21.65%. Mainly due to the company's continued implementation of key product focus strategy, strengthening 'one product one policy', sales revenue of 60 key varieties 5.158 billion yuan, an increase of 30.19%.

The pharmaceutical business realized a revenue of 66.252 billion yuan, a year-on-year increase of 13.69%, and a net profit of 2.033 billion yuan, a year-on-year increase of 5.62%. During the reporting period, the acquisition of distribution business in Jiangsu, Shanghai, Liaoning, Guizhou, Sichuan, Anhui, Hainan and other provinces deepened. These provinces focus on city-level business coverage. The integration of the drug Condola progressed as scheduled during the reporting period.

In addition, participation enterprise Contributed to profit of 353 million yuan, contributing net profit increased by 11.58%; pharmaceutical retail actively participated in the Shanghai community comprehensive reform prescription extension project, assisted in grading diagnosis and treatment, currently covering 230 communities in Shanghai hospital And the health service center, with a market share of nearly 70%. In the first half of 2018, the cumulative number of prescriptions was over 410,000, and the prescription volume increased by 115.4%.

In the first half of 2018, the company strictly implemented the business plan formulated at the beginning of the year. All the work was effective and achieved steady growth in business performance. The company achieved operating income of 4.651 billion yuan, a year-on-year increase of 78.34%; net profit of 2.059 billion yuan, an increase over the same period last year. 251.32%.

The company's continued growth, the main reasons for the substantial increase in net profit are as follows: 1 Adhere to the marketing concept of 'creating demand, serving customers', the business has achieved substantial growth, the company's spices increased by 56.73% over the same period of last year, maintaining a good Growth rate; the nutrition business achieved a growth rate of 86.98%. 2 Since 2017, vitamin prices have continued to rise, supply is in short supply, and net profit levels have increased significantly.

Note: The data comes from the Eastern Fortune Network, and the classification is based on the amount of net profit.